Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025.

CEO Amir Reichman to meet investors, pharma partners, and CDMO clients at global biotech conference

Recent SEPA Funding Enhances Operational Flexibility

Last week, Scinai raised $1.38 million in gross proceeds through drawdowns under its Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors. The funding was executed at a volume-weighted average price of approximately $3.03 per ADS, reflecting a 3% discount to market, and was completed without any warrants, fees, or additional dilution mechanisms. The proceeds strengthen Scinai's balance sheet and provide additional capital to advance both its CDMO growth and R&D programs. The company is now accelerating supplier and partner engagements in order to advance its nanobody pipeline toward IND-enabling studies, while simultaneously working to expand CDMO capacity and marketing outreach.

CDMO Business Scales Rapidly; 2025 Revenue Expected to Reach $2M

Scinai's Q1 2025 financial results, released last month, showed rapid growth in CDMO revenues, nearly matching full-year 2024 revenues in just the first quarter. Based on strong demand and capacity utilization, the company has issued 2025 revenue guidance of approximately $2 million. Scinai currently anticipates its CDMO unit will reach breakeven by end of 2026, with long-term revenue potential of $12 million annually under a single production shift, scalable further with additional shifts.

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Scinai Publishes Financial Results and Provides Business Update; Shareholders’ Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices unit, today announced that it will be showcasing its innovative I&I product pipeline in partnership meetings and exhibiting its CDMO services at the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden.

Scinai’s CEO, Mr. Amir Reichman, and CTO, Dr. Dalit Weinstein-Fischer will be holding meetings during the conference days with:

·         Prospective clients of the company’s end-to-end biologics CDMO services.

·         Potential pharma partners in the field of I&I interested in co-developing or in-licensing one of Scinai’s innovative NanoAbs.

·         Potential pharma partners in the field of dermatology interested in Scinai’s drug development program for local treatment of mild to moderate plaque psoriasis – “the Botox-like solution for psoriatic patients”

·         Institutional and private investors interested in SCNI’s value proposition.

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies